急性白血病患儿使用左旋门冬酰胺酶中凝血象监测的价值  

Blood Coagulation Function test for Acute Leukemia Patient under the Therapy of L-Asaraginase

作　　者：张文英[1] 徐涛[1] 

机构地区：[1]广州市儿童医院,广州510120

出　　处：《血栓与止血学》2006年第5期206-207,共2页Chinese Journal of Thrombosis and Hemostasis

摘　　要：目的研究急性淋巴细胞白血病(ALL)患儿使用左旋门冬酰胺酶(L-ASP)中凝学象的变化。方法27例ALL患儿,以Clauss凝固法测定血浆凝血酶原时间(PT)；活化部分凝血活酶时间(aPTT)以及纤维蛋白原(Fbg)。结果27例ALL患儿共51人次在使用L-ASP中,凝血检查结果均出现异常。Fbg为敏感的指标,其中使用剂量为2万u/m^2时患儿60．3%(31/51例)出现Fbg下降,而使用剂量为4万u/m^2时患儿86．3%(44/51例)出现Fbg明显下降。结论ALL患儿在使用L-ASP治疗中容易出现Fbg下降,下降程度与剂量相关,PT与aPTT不受其影响。检测凝血象对掌握病情,药物使用安全性有重要价值。Objective Study L-Asaraginase （L-ASP） . Methods blood coagulation function for acute leukemia patient under the therapy of 27 patients of acute leukemia, undergo the test of prothrombin time , actirated partial thromboplastin time and plasma fibrinogen by claus＇ s methods. Results 27 patient in 51 times L- ASP procedure shows abnormal. Fbg is the most sensitive, with dosage 20 000 u/m^2 60.3 % （31/51 case） shows decrease of the level of Fbg, and with dosage 40 000 u/m^2 86.3% （44/51 case） shows significant decrease. Conclusion acute Leukemia patient under the therapy of L-ASP are ease to get decrease of the level of Fbg, the severity of decline is relate to L-ASP dosage. PT, aPTT are not related to L-ASP usage . Blood coagulation function test is important for monitor of process in therapy, and the safe use of medicine.

关 键 词：急性淋巴细胞性白血病 凝血 左旋门冬胺酰胺酶 

分 类 号：R733.71[医药卫生—肿瘤]